BSE - Delayed Quote INR

Novartis India Limited (NOVARTIND.BO)

Compare
1,090.30 +34.60 (+3.28%)
At close: November 29 at 3:48 PM GMT+5:30
Loading Chart for NOVARTIND.BO
DELL
  • Previous Close 1,055.70
  • Open 1,051.05
  • Bid 1,095.75 x --
  • Ask 1,095.80 x --
  • Day's Range 1,050.00 - 1,098.00
  • 52 Week Range 693.20 - 1,248.00
  • Volume 3,920
  • Avg. Volume 10,638
  • Market Cap (intraday) 26.92B
  • Beta (5Y Monthly) 0.31
  • PE Ratio (TTM) 30.77
  • EPS (TTM) 35.43
  • Earnings Date Jan 23, 2025 - Jan 27, 2025
  • Forward Dividend & Yield 25.00 (2.29%)
  • Ex-Dividend Date Jul 23, 2024
  • 1y Target Est --

Novartis India Limited operates as a healthcare company in India. The company offers therapeutic products in the areas of bone and pain products under the Voveran brand; transplantation immunology products under the Simulect, Certican, Sandimmun, Neoral, and Myfortic brands. It also offers neurosciences products under the Tegrital and Exelon brands. Novartis India Limited was incorporated in 1947 and is based in Mumbai, India. The company is a subsidiary of Novartis AG.

www.novartis.in

62

Full Time Employees

March 31

Fiscal Year Ends

Recent News: NOVARTIND.BO

View More

Performance Overview: NOVARTIND.BO

Trailing total returns as of 11/29/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

NOVARTIND.BO
44.08%
S&P BSE SENSEX
10.47%

1-Year Return

NOVARTIND.BO
59.22%
S&P BSE SENSEX
20.60%

3-Year Return

NOVARTIND.BO
54.05%
S&P BSE SENSEX
39.74%

5-Year Return

NOVARTIND.BO
86.50%
S&P BSE SENSEX
94.02%

Compare To: NOVARTIND.BO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NOVARTIND.BO

View More

Valuation Measures

Annual
As of 11/29/2024
  • Market Cap

    26.92B

  • Enterprise Value

    21.00B

  • Trailing P/E

    30.81

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    7.83

  • Price/Book (mrq)

    3.69

  • Enterprise Value/Revenue

    6.10

  • Enterprise Value/EBITDA

    16.67

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    25.33%

  • Return on Assets (ttm)

    5.47%

  • Return on Equity (ttm)

    12.21%

  • Revenue (ttm)

    3.45B

  • Net Income Avi to Common (ttm)

    874M

  • Diluted EPS (ttm)

    35.43

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.97B

  • Total Debt/Equity (mrq)

    0.83%

  • Levered Free Cash Flow (ttm)

    591.83M

Research Analysis: NOVARTIND.BO

View More

Company Insights: NOVARTIND.BO

Research Reports: NOVARTIND.BO

View More

People Also Watch